This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

GAOMA Therapeutics


GAOMA develops new therapeutic molecules, with a particular focus on epilepsy and cognitive disorders. GAO-3-02 is a novel patented active ingredient, with an innovative MoA for the treatment of epilepsy. In various preclinical PoC studies, it demonstrated its ability to limit seizures but also to protect/restore cognitive functions, both on the long term. The company will also rapidly explore the interest of GAO-3-02 in other indications.